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Is necessary a speciﬁc quality assurance guidance for current brachytherapy?
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Introduction. Brachytherapy has evolved from the traditional surgical paradigm to modern three-dimensional image-based plan-
ning and delivery approaches.
Objectives. To analyse the international recommendations in brachytherapy quality assurance (QA) and the situation in Spain.
Materials and methods. We have reviewed international recommendations and the Spanish reality regarding brachytherapy QA.
In all international documents about brachytherapy QA there is a distinction between QA device (periodic testing of planning,
delivery and imaging systems) and QA clinical process (patient-speciﬁc treatment procedures). Different proactive tools are used
for a QA analysis, being the more used the failure mode and effect analysis (FMEA). It has three steps: ﬁrst, generate an overview
of the entire process (process map), in which all the nodes of the brachytherapy process are represented. Second, identify possible
failure nodes in every part of the process. Third, develop process improvements lowering the overall risk for each failure node.
The current Spanish RD1566/1998 (Quality Criteria in Radiotherapy), RD815/2001 (Justiﬁcation of medical exposure to ionizing
radiation) and Libro Blanco SEORXXI, deal with this subject.
Results. Available brachytherapy QA international recommendations are relatively ﬁxed protocols of speciﬁc tests, endpoints,
tolerances and frequencies that have been developed by small panels of experts and reﬂect practice patterns that predate the
image-based planning era. There is not unanimity in QA guidance. In our country there is no document/guide for brachytherapy
QA. Spanish RD do not include speciﬁc recommendations. There are mandatory legal regulations for radiotherapy procedures in
Spain with a punitive character. The Libro Blanco reﬂects the lack of studies and recommendations in brachytherapy QA.
Conclusions. Due to the complexity and variability of image-based brachytherapy procedures, a risk-based guide including clear
general QA protocols guidelines for the speciﬁc clinical implementations, is urgently needed.
http://dx.doi.org/10.1016/j.rpor.2013.03.708
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Purpose. To analyze the results of HDR brachytherapy (HDRBT) administered daily on local control and toxicity in postoperative
endometrial carcinoma (EC).
Materials and methods. From January 2007 to September 2010, 112 patients with FIGO Stage 24-IA, 48-IB, 14-II, 12-IIIA, II-IIIB, 8-IIIC1
and 4-IIIC2, were treated with HDRBT after surgery. Pathology: 99/112 endometrioid and 23/112 other types. Radiotherapy (two
groups of patients): Group 1: 70/112 external beam irradiation (EBI) +HDRBT (2 fractions 5–6Gy); Group 2: 42/112 HDRBT alone (4
fractions 5–6Gy). Toxicity evaluation: RTOG scores for bladder and rectum; objective criteria of LENT-SOMA for vagina.
Statistics. Chi-square and Fisher exact test.
Results. With a mean follow-up of 37 months (range 9.6–79.3) one patient developed vaginal-cuff relapse after 11 months (Group
1). Toxicity. Group 1: early G1–G2 appeared in 9% in rectum, 8.3% bladder, 1.4% in vagina; late problems appeared in 8.5% in
rectum (all G1–2 but 2 G3) and 29.1% in vagina (all G1–2 but 1 G4). Group 2: Early G1–2 toxicity 9.4% in bladder, 6.9% in vagina; late
problems only appeared in 23.8% in vagina (G1–2).
Conclusions. Daily HDRBT using 2 fractions of 5Gy after EBI and 4 fractions of 5Gy as exclusive treatment was a safe regime in
terms of local control and toxicity. Group 1 had a higher incidence of late vaginal, rectal and bladder toxicity than group 2. In
patients treated with HDRBT alone only G1–G2 late vagina toxicity was observed.
http://dx.doi.org/10.1016/j.rpor.2013.03.709
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Background. Lip carcinoma has been successfully treated with LDR brachytherapy. High-dose-rate brachytherapy (HDR-BT) publi-
cations are scarce andwith short follow-up.Weanalyze the results andprognostic factors in invasive squamous-cell lip carcinoma
with HDR.
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Methods. From 1999 to 2010, 102 patients were implanted with rigid needles for HDR-BT, 54T1, 33T2 and 15T4. Twenty-one patients
underwent surgery plus BT for close/positive margin, 78 exclusive BT, and 3 external radiation therapy (ERT) plus BT boost. Nine
fractions of 5Gy were given in ﬁve days in 67%, nine fractions of 4.5Gy in 10% and other schemas in the rest, prescribed to a 90%
isodose. Five cases presented cervical nodes, and 3 were detected in the elective dissection (8 cases N+). Elective neck treatment
was performed in 23 cases, 8 with neck dissection, 4 with sentinel node, and 11 with ERT.
Results. Median follow-up was 45 months (2–143). There were ﬁve local failures and 10 nodal failures. The 5 and 10-year actuarial
local control was 94.6%, nodal regional control 88.6%, disease-free-survival 84.6% and cause-speciﬁc survival 93.2%. In the uni-
variate analysis T4 tumors had higher risk of local failure and T2 of regional relapse. All T1 tumors were controlled and two T2
were salvaged with surgery. T4 had lower risk of nodal failure than T2 cases because 66% received an elective neck treatment,
vs 22.6%. In the multivariate analysis, skin involvement was the only signiﬁcant factor for tumor progression.
Conclusions. HDR-BT yields excellent local control rates. Skin involvement increases risk of local and cervical recurrence. Elective
neck treatment should be done in T2-4 tumors or with skin or commissure involvement. Cervical surgery or sentinel node
technique should be the ﬁrst election, and HDR-BT can be a good alternative to surgery for treating the local tumor with very
good cosmetic and functional outcome.
http://dx.doi.org/10.1016/j.rpor.2013.03.710
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Purpose. Low dose rate (LDR) prostate brachytherapy is an accepted, effective and safe therapy for localized prostate cancer in
selected patients at intermediate risk. We analyzed oncologic outcome, side-effects and complications after I-125 brachytherapy
based on 13 years of experience.
Methods and materials. Between March 2000 and December 2006, 219 consecutive patients were treated with clinically localized
prostate cancer. No patients received external beam radiation. All patients underwent LDR prostate brachytherapy. Biochemical
failure was deﬁned according to the “Phoenix consensus”. Patients were stratiﬁed as low, intermediate, or high risk based on
D’Amico deﬁnition.
Results. The median follow up time for these 219 patients was 98 months; 9 had a clinical relapse and 32 had biochemical relapse.
The 13-year actuarial biochemical control was 80% (SD ±3%). The multivariate Cox regression analyses identiﬁed, Gleason score
as independent prognostic factors for biochemical failure. The actuarial biochemical control with Gleason score was 83% and
78% for patients with Gleason score of ≤6, and =7, respectively (P=0.000). The biochemical control was 77% and 82% (SD ±3%)
for patients with PSA≤10 and 10.1–20 respectively (P=NS). No patients reported incontinence after treatment. Acute urinary
retention was seen in 8 (3.6%) patients. Logistic regression showed that the most signiﬁcant factors which correlate with the
probability of catheterisation are the pre-treatment prostate volume and hormonal therapy.
Conclusions. The excellent long-term results and low morbidity presented, as well as the many advantages of prostate brachyther-
apy over other treatments, demonstrate that brachytherapy is an effective treatment for clinical organ-conﬁned prostate cancer
in patients with intermediate risk tumors.
http://dx.doi.org/10.1016/j.rpor.2013.03.711
Study of erectile function, IIEF’s test in patients treated with brachytherapy exclusive with seeds of I-125 in early
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Introduction. In this project we analyze the evolution of sexual function in patients treated with brachytherapy technique with
radioactive sources of I-125, using the IIEF test that analyzes the sexual sphere in the aspects related to ejaculation, libido and
orgasm ability.
Patients and method. It has been analyzed 256 patients affected by early prostate cancer, diagnosed between June 2002 and June
2008, mean age 64.3 years (46–79), in stage T1b 1 p., T1c 178 p., T2a 66p, and T2b 11 p. The mean PSA value was been 6.64ng/ml
(2.1–12.6). The pathological report showed an adenocarcinoma Gleason 2 in 4 p., Gl 4 in 22 p., Gl 5 to 41 p., Gl 6 in 181 p. and Gl
7 in 7 patients. It was performed a measurement of the IIEF test before implantation, 1 month, every 3 months to 2 years and
every 6 months to 5 years. The mean follow-up of patients was 40 months (2–72 months).
Results. The results showed normal erectile function after 172/256 p. (67.19%), previous DE in 84/256 p. (32.81%). After treatment
retain E.F. at 133/172 p. (77.3%). Transitory DE in 27%. In the aspect in relation to ejaculation the value was 3.01 (pretreatment 3.8)
(Question 9). To relate with the orgasm, was a value of 2.75 pretreatment vs 3, 45 (Question 10) and with respect to libido, was a
value of 5.59 vs 6.25 pretreatment (Questions 11 and 12).
